← Back to Search

Psychedelic

Psilocybin for Cancer(HOPE Trial)

Huntsman Cancer Institute, Salt Lake City, UT
PsilocybinPhase < 1Waitlist AvailableLed by Anna Beck, MDResearch Sponsored by University of Utah

HOPE Trial Summary

This trial will offer psilocybin therapy in a group setting with a decreased therapist to subject ratio in order to assess feasibility. Seven group therapy sessions will include prep, psilocybin, and integration sessions occurring on a weekly basis.

HOPE Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Select...
Someone who has been diagnosed with cancer and is currently undergoing treatment or has completed treatment within the last 26 weeks is eligible to participate in this study.

HOPE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Consent of patients with a cancer diagnosis or hematologic malignancy
Enrollment of patients with a cancer diagnosis or hematologic malignancy
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by duration
+8 more

Side effects data

From 2021 Phase 2 trial • 95 Patients • NCT02061293
44%
Headache
21%
Nausea
15%
Anxiety
8%
Suicidal Ideation
6%
Insomnia
6%
Depressed mood
4%
Abdominal pain upper
4%
Vomiting
4%
Corona virus infection
4%
Upper respiratory tract infection
4%
Viral upper resp. tract infection
4%
Alcohol poisoning
4%
Depression
4%
Pneumonia
2%
Biopsy cervix
2%
Illusion
2%
Urinary incontinence
2%
Palpitations
2%
Cataract
2%
Abdominal pain
2%
Toothache
2%
Pain
2%
Limb injury
2%
Muscle strain
2%
Blood pressure diastolic increased
2%
Blood pressure increased
2%
Back pain
2%
Musculoskeletal pain
2%
Myalgia
2%
Dizziness
2%
Psychomotor hyperactivity
2%
Alcohol withdrawal syndrome
2%
Dysphoria
2%
Testicular pain
2%
Hyperventilation
2%
Food poisoning
2%
Food allergy
2%
Dyspepsia
2%
Influenza
2%
Nasal congestion
2%
Skin cosmetic procedure
2%
Photopsia
2%
Diverticulitis
2%
Asthenia
2%
Fatigue
2%
Gingivitis
2%
Dyspnea
2%
Oropharyngeal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Psilocybin
Diphenhydramine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

HOPE Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment: all patientsExperimental Treatment1 Intervention
Subjects will participate in a total of seven group sessions. There will be 4 or 6 subjects per group and one therapist will be assigned to each subject for a total of 4 or 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are "Preparatory" sessions followed by three "Integration" sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin
2021
Completed Phase 2
~720

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,068 Previous Clinical Trials
1,710,217 Total Patients Enrolled
Usona InstituteOTHER
11 Previous Clinical Trials
506 Total Patients Enrolled
Anna Beck, MDPrincipal InvestigatorHuntsman Cancer Institute

Media Library

Psilocybin (Psychedelic) Clinical Trial Eligibility Overview. Trial Name: NCT04522804 — Phase < 1
Cancer Research Study Groups: Treatment: all patients
Cancer Clinical Trial 2023: Psilocybin Highlights & Side Effects. Trial Name: NCT04522804 — Phase < 1
Psilocybin (Psychedelic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04522804 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
South Carolina
Utah
Other
Florida
How old are they?
65+
18 - 65
What site did they apply to?
Huntsman Cancer Institute
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
3+

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Huntsman Cancer Institute: < 24 hours
Average response time
  • < 1 Day
~4 spots leftby Nov 2024